Sosei, AstraZeneca deal

Sosei’s Heptares Therapeutics Ltd. subsidiary granted AstraZeneca exclusive, worldwide rights to develop and commercialize cancer candidate HTL1071, an adenosine A2A ( ADORA2A) receptor inhibitor, and other preclinical A2A receptor inhibitors discovered under a new research deal. Heptares will get $10 million up front and is eligible to receive more than $500 million in development and commercialization milestones and double-digit royalties. ...